ARCHIVE SEARCH
      -OR-  
 
  NEWS CHANNELS
Fitness News
Asthma Allergy News
 > Diabetes News
Women's Health News
Men's Health News

  MY NEWS
Personal Archive
My Account

  ABOUT THIS NEWSFEED
About Us
Advertise With Us
Feed Your Site
Contact Us


Site Map
RSS News Feed 

  Website development & hosting
   by Cyber Software Solutions

 
Phentermine, Topiramate Reduce Progression to T2DM
Significant weight loss with extended-release tx for those with prediabetes/metabolic syndrome

MONDAY, Oct. 21 (HealthDay News) -- Over two years, phentermine and topiramate extended-release (PHEN/TPM ER) treatment plus lifestyle changes lead to significant weight loss and a considerable reduction in progression to type 2 diabetes in high-risk, overweight/obese individuals, according to a study published online Oct. 8 in Diabetes Care.

W. Timothy Garvey, M.D., from the University of Alabama at Birmingham, and colleagues conducted subanalysis of a phase 3, randomized, double-blind study of overweight/obese subjects (BMI ≥27 to ≤45 kg/m²) with two or more comorbidities. Participants were randomized to receive placebo, PHEN 7.5 mg/TPM ER 46 mg (7.5/46), or PHEN 15 mg/TPM ER 92 mg (15/92) plus lifestyle modifications for 108 weeks.

The researchers found that, at baseline, 475 participants had prediabetes and/or metabolic syndrome (MetS). The mean percent weight loss for these participants was 2.5, 10.9, and 12.1 percent, respectively, in the placebo, 7.5/46, and 15/92 groups after 108 weeks. Compared with placebo, there were reductions of 70.5 and 78.7 percent in the annualized incidence rate of type 2 diabetes for the 7.5/46 and 15/92 groups, respectively. The reductions correlated with the degree of weight loss and were accompanied by significant cardiometabolic parameter improvements. Over two years, PHEN/TPM ER was well tolerated.

"PHEN/TPM ER plus lifestyle modification produced significant weight loss and markedly reduced progression to type 2 diabetes in overweight/obese patients with prediabetes and/or MetS," the authors conclude.

Several authors disclosed financial ties to pharmaceutical companies, including VIVUS, which funded the study and manufactures PHEN/TPM ER.

Abstract
Full Text (subscription or payment may be required)



Copyright © 2013 HealthDay. All rights reserved.


Back to Top Stories
  GOOGLE ADS